Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC monotherapy in HER2-expressing gynecologic malignancies
CTR20211602Phase 2Active
- Sponsor
- RemeGen
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapoxetine in gynecological cancer, Cervical Cancer (CC), epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by RemeGen. Started Dec 2021; status: active.
02
Drugs
dapoxetine
03
Conditions
gynecological cancerCervical Cancer (CC)epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20211602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211602.